Sustained Release, Inc. is working with Akina Inc. on the licensing and commercial development of their innovative delivery technologies for pharmaceutical compounds.
Akina has developed a technology to provide a refined production method for measured time release distribution of pharmaceutical compounds. Unlike current time-released technology, Sustained Release formulated drugs can be administered to patients so they receive the medications consistently over periods ranging from one week up to one year.
Sustained Release will manage the process to finance the development and commercialization of these delivery technologies in collaboration with Akina. A key feature of the technology Akina has developed is the ability to formulate a wide range of drug types, including proteins. Current technology is very limited in the types of drugs that can be used.
Akina will manage the formulation, development and animal modeling of the specific identified pharmaceutical compounds and Sustained Release will be responsible for providing Akina with development funding and subsequent licensing or partnering arrangements to commercialize the compounds developed.
Improving the quality of care for patients with Type II Diabetes, Prostate Cancer, and Chronic Pain Management needs is our primary focus. Additional medications are in review for phase 2 of our development.
Nathan Blumberg, M.D.
Chairman of the Board of Directors
Practiced Urology in Suffolk County, NY, from 1970 through 2009. For the past 5 years has been organizing Sustained Release projects including the oversight and selection of all pharmaceutical candidates for inclusion in the Akina delivery system and development of the biodegradable ureteral stent.
Dr. Rob Shorr
Dr. Shorr has focused most of his career on the research and discovery of the biochemical basis of neurotransmitter and hormone receptors and the design and discovery of therapeutic agents. As CEO of Cornerstone Pharmaceuticals, he focused on the development, human clinical trials, and FDA approvals of safe and effective novel drugs as well as delivery technology for dramatic improvements in cancer disease management. He also served as VP, Science and Technology/Chief Scientist for United Therapeutics/Unither, where he invented PEGylated prostacylcin for pulmonary hypertension. As VP of Science and Technology for Enzon Inc., he was responsible for the development and regulatory approval of the blockbuster drug PEG INTRON A, and contributed to the discovery and development of PEGylated proteins and small molecule drugs.
CEO and Board of Directors member
Served as President and Manager/Member of Micro-Imaging Solutions LLC, a company engaged in the development and commercialization of imaging systems for medical applications. Former president and Director of GENESIS Corporation which joined with DMI BioSciences, Inc. in 2004 to participate in the development of compounds for the treatment of asthma and multiple sclerosis in humans. DMI later merged with Ampio Pharmaceutical Corp. Ampio is currently traded on the NYSE symbol AMPE.
J. Gregory Swendsen
Board of Directors member
President of Swendsen & Company, a financial management company founded in 1984 that specializes in seed and venture capital in the life sciences and applied technologies. Mr. Swendsen is a founder of SuperGen, Inc. a leading developer of anti-cancer drugs, a founder of Quark Pharmaceuticals, Inc., which was acquired by SBI Biotech in 2012, and served on the Board of Directors of AMUR Pharmaceuticals prior to its sale to SuperGen. He also currently serves on the board of directors of American Life Science Pharmaceuticals, Inc., a clinical stage Alzheimer’s and neurodegenerative disease company.